MedTrace Logo

Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock

NCT03437369 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2018-02-19

No results posted yet for this study

Summary

This is a randomized 1:1 blinded study that evaluate in acute left heart failure-cardiogenic shock patients if ivabradine treatment can reduce pulmonary wedge pressure, without inducing a significant or relevant reduction in cardiac output or increasing the risk of arterial hypotension and with the benefit of allowing a faster titration of heart failure drugs.

Conditions

  • Cardiogenic Shock

Interventions

DRUG

Ivabradine Oral Tablet

The target dose is 10 to 15 mg / day, administered orally in two doses

OTHER

Standard of Care treatment

The study drug will be compared with the standard of Care treatment

Sponsors & Collaborators

  • Hospital Universitario Ramon y Cajal

    lead OTHER

Principal Investigators

  • Marcelo Sanmartín Fernández, PhD · Hospital Universitario Ramon y Cajal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-31
Primary Completion
2019-10-31
Completion
2019-10-31
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03437369 on ClinicalTrials.gov